Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rapport Therapeutics (RAPP) Income from Continuing Operations (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Income from Continuing Operations data on record, last reported at 19857000.0 in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 17.48% to 19857000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 107277000.0, a 34.6% decrease, with the full-year FY2025 number at 111483000.0, down 42.37% from a year prior.
  • Income from Continuing Operations reached 19857000.0 in Q1 2026 per RAPP's latest filing, up from 33763000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for RAPP hit a ceiling of 6411000.0 in Q2 2023 and a floor of 33763000.0 in Q4 2025.
  • A 4-year average of 19241333.33 and a median of 18989000.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 182.65% in 2024, then rose 17.48% in 2026.
  • Tracing RAPP's Income from Continuing Operations over 4 years: stood at 13519000.0 in 2023, then tumbled by 47.79% to 19980000.0 in 2024, then tumbled by 68.98% to 33763000.0 in 2025, then skyrocketed by 41.19% to 19857000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for RAPP at 19857000.0 in Q1 2026, 33763000.0 in Q4 2025, and 26925000.0 in Q3 2025.